NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Pharming Group N.v. PHAR
8 fiscal years on record · USD · FY2025 reported · SEC filings only
In brief
What this company does
Written from the business description in Pharming Group N.V.'s annual report to the U.S. Securities and Exchange Commission, filed 2 April 2026. Every sentence was checked against that document before publication.
Growth
USD 376.1M
Revenue, FY2025 · full 8-year series below
Revenue $M
Net income $M
FY2025 · Revenue 376.1 · Net income 2.9
Compound annual growth
Revenue compounded at +12.1% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
1 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 6.9% · Net 0.7%
ROE
Not available in our data for this period.
The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | · |
| Operating income $B | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.1 | 0.1 | · |
| EBITDA $B | · | · | · | · | 0.0 | 0.1 | 0.1 | 0.0 |
| Income tax $B | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income $B | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Free cash flow $B | 0.1 | −0.0 | −0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 |
| EPS, diluted $ | 0.00 | −0.02 | −0.02 | 0.02 | 0.02 | 0.06 | 0.06 | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · |
| Shares out B | 0.70 | 0.68 | 0.67 | 0.66 | 0.65 | 0.64 | 0.63 | 0.62 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 2 failures in 39 reconciliationsAUDITED
Reconciled in 7 of 19 fiscal years. 56 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code P7
Fiscal year endsDecember 31
Data on record since2017